StockMarketWire.com - Tiziana Life Sciences, which is developing drugs targeting cancer and inflammatory diseases, said it had received a positive evaluation of tolerability data for a treatment for hepatocellular carcinoma.
An independent data monitor committee recommended an expansion of an initial 11-patient cohort to an additional 20 patients to complete a trial.
'Demonstration of good tolerability with acceptable incidence of serious adverse events is an important milestone,' the company said.
At 9:31am: [LON:TILS] Tiziana Life Sciences Plc share price was +0.75p at 81.75p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.